Subcutaneous C1 Inhibitor May Reduce Angioedema Attacks
The study results showed that compared with placebo, both doses of CSL830 reduced the rate of attacks of hereditary angioedema
Hereditary Angioedema
Pediatric Treatment for Hereditary Angioedema Gets FDA Approval
CSL Behring announced that the Food and Drug Administration (FDA) has approved the use of Berinert (C1 esterase inhibitor [human]) for the treatment of hereditary angioedema (HAE) attacks in pediatric patients.
Treatment Options for Managing ACEI-Induced Angioedema
For the management of angiotensin-converting enzyme inhibitor (ACEI)-induced angioedema, use of fresh frozen plasma and complement 1 esterase (C1) inhibitor appear to be safe and effective whereas ecallantide should be avoided, a study published in the American Journal of Health-System Pharmacy concluded.
Hereditary Angioedema Tx Now a Breakthrough Therapy
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the investigation of DX-2930 (Dyax) for hereditary angioedema (HAE).
First-in-Class Drug Launched for Hereditary Angioedema
Salix and Pharming Group announced the launch of Ruconest (C1 esterase inhibitor [recombinant]) injection for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE).
Ruconest Approved for Acute Angioedema Attacks in HAE
Salix and Pharming Group NV announced that the FDA has approved Ruconest (C1 Esterase Inhibitor [Recombinant]) for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema (HAE).
Kalbitor Inj Indication Expanded to Pediatric Patients
Dyax announced that the FDA has expanded the indication for Kalbitor (ecallantide) to include patients >12 years old.
Ruconest BLA Under Review for Acute Hereditary Angioedema
The FDA has accepted for review Santarus and Pharming’s Biologics License Application for Ruconest (INN conestat alfa) 50 IU/KG, a recombinant human C1 esterase inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema.
rhC1INH Cuts Attack Frequency in Hereditary Angioedema
For patients with hereditary angioedema (HAE), weekly administration of recombinant C1INH (rhC1INH) is well tolerated and is associated with a reduction in attack frequency.
Phase 3 Trial Update of Ruconest for Acute Hereditary Angioedema
Santarus and Pharming Group NV announced that their Phase 3 clinical study of Ruconest (recombinant human C1 esterase inhibitor) for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema (HAE) met its primary endpoint.
